ERBB2 and gastric cancer: Most patients in these cohorts were diagnosed with stage IV GC, with a prevalence of 98.52% in the anti-HER2 cohort, 97.48% in the anti-HER2 combined immunotherapy cohort, and 97.44% in the external cohort.